Table 1.

Characteristics of patients with ANCA-associated GN at the time of trial enrollment stratified by presence of persistent hematuria

Characteristic	All, n=149	Persistent Hematuria beyond 6 mo
		Yes, n=63	No, n=86
Age, yr	55 (44–66)	54 (43–68)	55 (44–63)
Women, %	41	56	30
Achieved menopause (if a woman), %	62	51	77
Race, %
White	93	92	94
Black	3	3	2
Other	4	5	3
ANCA-associated vasculitis type, %
Granulomatosis with polyangiitis	81	71	87
Microscopic polyangiitis	19	29	13
ANCA type by ELISA, %
Anti-PR3	68	65	71
Anti-MPO	32	35	29
Duration of trial enrollment, mo	36 (24–43)	36 (25–46)	36 (24–42)
Newly diagnosed, %	59	57	60
BVAS/GPA	7 (5–10)	8 (6–10)	7 (4–9)
Vasculitis damage index	0 (0–1)	0 (0–1)	0 (0–1)
Pulmonary involvement, %	60	54	65
Alveolar hemorrhage, %	26	30	23
Induction therapy, %
Cyclophosphamide	66	54	76
Rituximab	34	46	24
Cumulative dose of cyclophosphamide before enrollment, g	0.8 (0–24.0)	0 (0–26)	1.2 (0–17.6)
Characteristics of kidney disease
Prior kidney involvement, %	98	100	94
Ever required dialysis, %	3	3	2
Serum creatinine at enrollment, mg/dl	1.4 (1.1–2.3)	1.8 (1.1–2.6)	1.3 (1–2.2)
Manifestations at enrollment, %
Hematuria	100	100	100
Proteinuria	74	86	66
Red blood cell castsa	56	62	52
Rise in serum creatininea	50	63	41
Duration of persistent hematuria, mo	6 (3–12)	17 (11–26)	3 (2–4)
Persistent proteinuria ≥6 mo, %	43	60	31

Values are expressed as medians (interquartile ranges) or percentages. he conversion factor for serum creatinine in milligrams per deciliter to micromoles per liter is ×88.4. PR3, proteinase 3; MPO, myeloperoxidase; BVAS/GPA, Birmingham Vasculitis Activity Score for Granulomatosis with Polyangiitis.

^aOn the basis of Birmingham Vasculitis Activity Score for Wegener Granulomatosis items.